MRD / Regn No. : 20220000593 Date : 24/06/2026
Patient Name : Sarveswaran Thiruprathangan Age & Gender : 62 Yrs. / Male
Contact No. : 9941161113 UHID :
Ht / Wt / BMI : 159.5 / 63.3 / 24.88 BP S / BP D : 135 / 76
Allergies : NKA Referred By :
   
Problem List : TYPE 2 DM (02/Jun/2002) | BENIGN PROSTATIC HYPERPLASIA (17/Nov/2022) |
Subjective : FOLLOW UP VISIT
Objective : NONE
Analysis : TYPE 2 DM WELL CONTROLLED
Plan : INCREASE SEMAGLUTIDE TO 1 MG,DECREASE INSULIN TO 18-01-2 UNITS  
Salient Investigations : FASTING PLASMA GLUCOSE (FPG): 106 mg/dL | POST PRANDIAL GLUCOSE (2HPP): 101 mg/dL
S# Generic (Trade) Name Route Dosage Usage Duration
1 INJECTION DEGLUDEC / ASPART (INJ U100) 70/30
RYZODEG
Medicine For DIABETES
SQ 18-0-12 UNITS BEFORE FOOD
TILL NEXT VISIT
MAY CAUSE HYPOGLYCEMIA
2 TABLET DAPAGLIFLOZIN 10 MG PIOGLITAZONE 15 MG
UDAPA PRO
Medicine For DIABETES MASLD
PO 1-0-0 BEFORE FOOD
TILL NEXT VISIT
MAY CAUSE GU INFECTIONS AND FEET SWELLING
3 INJECTION SEMAGLUTIDE 1 MG
SEMASIZE 1 MG
Medicine For DIABETES OBESITY HEART PROTECTION
SQ ONCE A WEEK AS DIRECTED NO RELATION TO FOOD
TILL NEXT VISIT
MAY CAUSE NAUSEA VOMITING OR VISUAL DISTURBANCE
       
Refill : 0 / Substitution:    
Education :
Next Visit : 24/Aug/2026
Tests Suggested For Next Visit : FBS 2HPP HBA1C
   
   

Dr. Krishna G Seshadri
Sr. Consultant Endocrinology Diabetes and Metabolism
Tamil Nadu / 48748 HPRID: 71-0638-2075-7542

This is a Computer generated Prescription

Powered By: